High-fidelity DNA synthesis using enzymes
Dahlia Biosciences is harnessing CRISPR-Cas9 technology to develop the next generation of in situ nucleic acid detection reagents for cell and tissue analysis.
GeneTether is an early stage startup focussing on developing high efficiency precision gene editing for human therapeutics and agbio applications.
Reformer Therapeutics is an immuno-oncology drug development company focused on identifying new therapies in areas of unmet need. Our first lead, RFR-001, is a Phase II small molecule that we are developing in triple-negative breast cancer. We have additional leads that we are evaluating for further development in additional oncology indications and inflammation.
Soteria Biotherapeutics is developing next-generation small-molecule-activated protein switches for controlling the activity of immunomodulatory therapeutics such as CAR T-cells.
Tulavi Therapeutics is dedicated to developing new therapies to treat neurally mediated disease.